Şunu aradınız:: hemopoetini (Litvanca - İngilizce)

nra kito zinomo busilvex antidoto, tik kamienini hemopoetini lsteli transplantacija.
there is no known antidote to busilvex other than haematopoietic progenitor cell transplantation.

busilvex skiriamas pries prast hemopoetini kamienini lsteli transplantacij (hklt) .
busilvex is administered prior the conventional haematopoietic progenitor cell transplantation (hpct) .

jums bus skiriamas sis vaistas pries atliekant kaul ciulp ar hemopoetini kamienini lsteli transplantacij.
you will receive this preparative medicine before receiving a transplant of either bone marrow or haematopoietic progenitor cell.

jeigu negalima atlikti kamienini hemopoetini lsteli transplantacijos, rekomenduojamos busilvex dozs reiks busulfano perdozavim.
in the absence of haematopoietic progenitor cell transplantation, the recommended dosage of busilvex would constitute an overdose of busulfan.

busilvex turi skirti gydytojas, turintis patirties skirti palaikomj gydym pries hemopoetini kamienini lsteli transplantacij.
busilvex administration should be supervised by a physician experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation.

nstumas kamienini hemopoetini lsteli transplantacijos negalima atlikti nscioms moterims, todl busilvex negalima vartoti nstumo metu.
pregnancy hpct is contraindicated in pregnant women; therefore, busilvex is contraindicated during pregnancy.

buvo tiriamas busilvex poveikis pacientams, kuri dauguma sirgo kraujo vziu ir kuriems buvo reikalinga hemopoetini kamienini lsteli transplantacija.
busilvex has been studied in patients, mainly with blood cancer, who needed transplantation of haematopoietic progenitor cells.

busilvex skiriamas palaikomajam (paruosiamajam) gydymui pries hemopoetini kamienini lsteli (lsteli, gaminanci kraujo knelius) transplantacij suaugusiems pacientams ir vaikams.
busilvex is used in adults and children as a conditioning (preparative) treatment before transplantation of haematopoietic progenitor cells (cells that make blood cells) .

17 bendradarbiaujant su onkologijos- hematologijos centru, kuris turi pakankamai patirties šioje srityje ir kur gali būti tinkamai atliekamas hemopoetinių kamieninių ląstelių stebėjimas.
18 collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed.